LA JOLLA, CA / ACCESSWIRE / November 11, 2020 / Artelo Biosciences, Inc. (NASDAQ:ARTL), a clinical stage biopharmaceutical company developing therapeutics that modulate endogenous signaling pathways, including the endocannabinoid system, today announced that it will be presenting at the Virtual Fall Investor Summit to be held virtually on November 16-18, 2020.
Gregory D. Gorgas, President and Chief Executive Officer of Artelo Biosciences, is scheduled to present on Wednesday, November 18th at 11:30 a.m., Eastern Time. The presentation will be webcast live and available for replay at https://www.webcaster4.com/Webcast/Page/2038/38410. One-on-one meetings will be held throughout the conference via video conference calls.
To register for the conference or schedule one-on-one meeting with Artelo Biosciences, please contact your Investor Summit Group representative or visit https://investorsummitgroup.com/.
About Artelo Biosciences
Artelo Biosciences, Inc. is a San Diego-based biopharmaceutical company dedicated to the development and commercialization of proprietary therapeutics that modulate endogenous signaling pathways, including the endocannabinoid system and related pathways. Artelo is rapidly advancing a portfolio of broadly applicable product candidates designed to address significant unmet needs in multiple diseases and conditions, including anorexia, cancer, pain, and inflammation. Led by proven biopharmaceutical executives collaborating with highly respected researchers and technology experts, the company applies leading edge scientific, regulatory, and commercial discipline to develop high-impact therapies. More information is available at www.artelobio.com and Twitter: @ArteloBio.
Investor Relations Contact:
Crescendo Communications, LLC
Tel: 212-671-1020
Email: ARTL@crescendo-ir.com
SOURCE: Artelo BioSciences
View source version on accesswire.com:
https://www.accesswire.com/615942/Artelo-Biosciences-to-Present-at-the-Virtual-Fall-Investor-Summit-on-November-18th
